Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
IDO1 (mouse) (rec.) (His)
Product Details | |
---|---|
Synonyms | Indoleamine 2,3-dioxygenase 1; IDO; INDO |
Product Type | Protein |
Properties | |
Source/Host | E. coli |
Sequence |
Mouse IDO1 (aa 1-407) is fused at the C-terminus to a His-tag. |
Crossreactivity | Mouse |
Biological Activity |
Specific Activity: >100’000U/mg protein with L-tryptophan as substrate and after addition of 7μM hemin for protein induction. One unit is defined as the amount of enzyme that produces 1nmol of kynurenine per hour. |
MW | ~40kDa (SDS-PAGE) |
Purity | ≥90% (SDS-PAGE) |
Endotoxin Content | <1EU/μg purified protein (LAL test; Lonza). |
Concentration | 1mg/ml |
Formulation | Liquid. 0.2μm-filtered solution in 50mM TRIS-Cl, pH 7.4, containing 1mM EDTA. |
Other Product Data |
UniProt link P28776: Indoleamine 2,3-dioxygenase 1 (mouse) |
Shipping and Handling | |
Shipping | BLUE ICE |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Handling Advice |
After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. For maximum product recovery after thawing, centrifuge the vial before opening the cap. |
Use/Stability |
Stable for at least 2 years after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. |
Documents | |
MSDS | Download PDF |
Product Specification Sheet | |
Datasheet | Download PDF |
IDO1 is a heme enzyme that catalyzes the first and rate-limiting step in the main pathway of human tryptophan catabolism, the kynurenine pathway, causing depletion of tryptophan which can lead to halted growth of microbes as well as T cells. IDO1 is an immune checkpoint protein, thought to play a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation and antioxidant activity. Cancer cells are able to evade the immune system is by hijacking the checkpoint proteins. Increased IDO1 protein levels drive growth arrest and apoptosis of the effector T cells, a group of immune cells that mediate the immune system’s ability to destroy pathogens. By reducing the number of effector T cells, IDO1 overexpression prevents the immune system from effectively destroying cancer cells. IDO1 overexpression has been observed in a wide range of human cancers such as prostatic, colorectal, pancreatic, cervical, gastric, ovarian, head or lung cancer. Physiological IDO1 activity has been implicated in T cell tolerance to tumors, dysfunctional selftolerance in non-obese diabetic (NOD) mice, and as a protective negative regulator in autoimmune disorders.